Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro

  • L. Herrera
  • , R. A. Farah
  • , V. A. Pellegrini
  • , D. B. Aquino
  • , E. S. Sandler
  • , G. R. Buchanan
  • , E. S. Vitetta
  • University of Texas Southwestern Medical Center
  • Children's Medical Center Dallas
  • Pediatric Oncology Group

Producción científica › revisión exhaustiva

65 Citas (Scopus)

Resumen

Monoclonal antibodies (Mabs) conjugated to toxins or their subunits (immunotoxins or ITs) are undergoing clinical testing in adults with a variety of malignancies. The potential impact of this form of therapy in pediatric precursor B-lineage acute lymphoblastic leukemia (pre-B ALL) has yet to be determined. Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in patients with pre-B ALL. Because of the encouraging performance of these ITs in phase I trials, we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient-derived pre-B ALL cells maintained in vitro on a stromal feeder layer. After 48 h in culture, cytotoxicity to tumor cells was determined by flow cytometry using propidium iodide (PI) and fluorescein isothiocyanate (FITC)-conjugated anti-CD10, 19, and 22. Both RFB4-dgRTA and HD37-dgRTA induced a statistically significant reduction in the number of viable leukemic cells, and Combotox was even more effective. Our results demonstrate that these ITs are specifically cytotoxic to primary pre-B ALL cells and that they should be further evaluated for the therapy of B-lineage ALL.

Idioma originalEnglish
Páginas (desde-hasta)853-858
Número de páginas6
PublicaciónLeukemia
Volumen14
N.º5
DOI
EstadoPublished - 2000
Publicado de forma externaSí

Huella

Profundice en los temas de investigación de 'Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro'. En conjunto forman una huella única.

Citar esto